| abstract |
Use of a soluble recombinant Neurregulin-1 isoform for the manufacture of a drug for the treatment of schizophrenia, in particular aspects of schizophrenia related to cognition, bipolar disorder and depression, Parkinson's disease, Alzheimer's disease, epilepsy, MS, ALS, stroke, traumatic brain injury and spinal cord injury, where the isoform of Neurregulin-1 is a soluble recombinant human Neurregulin-1 isoform and where the isoform of Neurregulin-1 has a molecular weight of approximately 10 to approximately 35 KD as measured by SDS-PAGE. |